Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
The evolving vaccine landscape: Insights from the 6th ESCMID Conference on Vaccines
The conference brought together the vaccine community and stakeholders, including industry representatives, clinicians, regulators, policymakers, academics,...